Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens

Daniel W. Cramer; Robert C. Bast; Christine D. Berg; Eleftherios P. Diamandis; Andrew K. Godwin; Patricia Hartge; Anna E. Lokshin; Karen H. Lu; Martin W. McIntosh; Gil Mor; Christos Patriotis; Paul F. Pinsky; Mark D. Thornquist; Nathalie Scholler; Steven J. Skates; Patrick M. Sluss; Sudhir Srivastava; David C. Ward; Zhen Zhang; Claire S. Zhu; Nicole Urban

doi:10.1158/1940-6207.CAPR-10-0195

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens

Daniel W. Cramer, Robert C. Bast, Christine D. Berg, Eleftherios P. Diamandis, Andrew K. Godwin, Patricia Hartge, Anna E. Lokshin, Karen H. Lu, Martin W. McIntosh, Gil Mor, Christos Patriotis, Paul F. Pinsky, Mark D. Thornquist, Nathalie Scholler, Steven J. Skates, Patrick M. Sluss, Sudhir Srivastava, David C. Ward, Zhen Zhang, Claire S. ZhuNicole Urban

School of Medicine

Research output: Contribution to journal › Article › peer-review

218 Scopus citations

Abstract

Establishing a cancer screening biomarker's intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity whenmoving to phase III specimens that had been drawn within 6months of the clinical diagnosis. Performance of all markers declined in phase III specimensmore remote than 6months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study.

Original language	English (US)
Pages (from-to)	365-374
Number of pages	10
Journal	Cancer Prevention Research
Volume	4
Issue number	3
DOIs	https://doi.org/10.1158/1940-6207.CAPR-10-0195
State	Published - Mar 2011

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1940-6207.CAPR-10-0195

Cite this

Cramer, D. W., Bast, R. C., Berg, C. D., Diamandis, E. P., Godwin, A. K., Hartge, P., Lokshin, A. E., Lu, K. H., McIntosh, M. W., Mor, G., Patriotis, C., Pinsky, P. F., Thornquist, M. D., Scholler, N., Skates, S. J., Sluss, P. M., Srivastava, S., Ward, D. C., Zhang, Z., ... Urban, N. (2011). Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research, 4(3), 365-374. https://doi.org/10.1158/1940-6207.CAPR-10-0195

Cramer, DW, Bast, RC, Berg, CD, Diamandis, EP, Godwin, AK, Hartge, P, Lokshin, AE, Lu, KH, McIntosh, MW, Mor, G, Patriotis, C, Pinsky, PF, Thornquist, MD, Scholler, N, Skates, SJ, Sluss, PM, Srivastava, S, Ward, DC, Zhang, Z, Zhu, CS & Urban, N 2011, 'Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens', Cancer Prevention Research, vol. 4, no. 3, pp. 365-374. https://doi.org/10.1158/1940-6207.CAPR-10-0195

@article{7478aeeca9a84275801fe476d98d3134,

title = "Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens",

abstract = "Establishing a cancer screening biomarker's intended performance requires {"}phase III{"} specimens obtained in asymptomatic individuals before clinical diagnosis rather than {"}phase II{"} specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity whenmoving to phase III specimens that had been drawn within 6months of the clinical diagnosis. Performance of all markers declined in phase III specimensmore remote than 6months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study.",

author = "Cramer, {Daniel W.} and Bast, {Robert C.} and Berg, {Christine D.} and Diamandis, {Eleftherios P.} and Godwin, {Andrew K.} and Patricia Hartge and Lokshin, {Anna E.} and Lu, {Karen H.} and McIntosh, {Martin W.} and Gil Mor and Christos Patriotis and Pinsky, {Paul F.} and Thornquist, {Mark D.} and Nathalie Scholler and Skates, {Steven J.} and Sluss, {Patrick M.} and Sudhir Srivastava and Ward, {David C.} and Zhen Zhang and Zhu, {Claire S.} and Nicole Urban",

year = "2011",

month = mar,

doi = "10.1158/1940-6207.CAPR-10-0195",

language = "English (US)",

volume = "4",

pages = "365--374",

journal = "Cancer Prevention Research",

issn = "1940-6207",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

TY - JOUR

T1 - Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens

AU - Cramer, Daniel W.

AU - Bast, Robert C.

AU - Berg, Christine D.

AU - Diamandis, Eleftherios P.

AU - Godwin, Andrew K.

AU - Hartge, Patricia

AU - Lokshin, Anna E.

AU - Lu, Karen H.

AU - McIntosh, Martin W.

AU - Mor, Gil

AU - Patriotis, Christos

AU - Pinsky, Paul F.

AU - Thornquist, Mark D.

AU - Scholler, Nathalie

AU - Skates, Steven J.

AU - Sluss, Patrick M.

AU - Srivastava, Sudhir

AU - Ward, David C.

AU - Zhang, Zhen

AU - Zhu, Claire S.

AU - Urban, Nicole

PY - 2011/3

Y1 - 2011/3

N2 - Establishing a cancer screening biomarker's intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity whenmoving to phase III specimens that had been drawn within 6months of the clinical diagnosis. Performance of all markers declined in phase III specimensmore remote than 6months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study.

AB - Establishing a cancer screening biomarker's intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity whenmoving to phase III specimens that had been drawn within 6months of the clinical diagnosis. Performance of all markers declined in phase III specimensmore remote than 6months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study.

UR - http://www.scopus.com/inward/record.url?scp=79953043818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953043818&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-10-0195

DO - 10.1158/1940-6207.CAPR-10-0195

M3 - Article

C2 - 21372036

AN - SCOPUS:79953043818

SN - 1940-6207

VL - 4

SP - 365

EP - 374

JO - Cancer Prevention Research

JF - Cancer Prevention Research

IS - 3

ER -

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this